This inventor holds 4 USPTO granted patents. Top assignees: Amrad Operations Pty Ltd, Frank Koentgen Pty Ltd., Other. Active years: 2000-2003.
Location History:
- Lower Templestowe, Victoria, AU (2001)
- Lower Templestowe, AU (2000 - 2003)
- Park Orchards, Victoria 3114, AU (2003)
Company Filing History:
1 out of 13 
1 out of 1 
2 out of 834,350 Years Active: 2000-2003
Title: Frank Koentgen: Innovator in Catalytic Antibodies
Introduction
Frank Koentgen is a notable inventor based in Park Orchards, Victoria, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of catalytic antibodies. With a total of 4 patents to his name, Koentgen's work has implications for therapeutic, diagnostic, and industrial applications.
Latest Patents
One of Koentgen's latest patents is focused on catalytic antibodies and a method of producing them. This invention relates to a growth factor precursor and its use in selecting the production of antigen-specific catalytic antibodies. The process involves B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor. A particularly innovative aspect of this invention is the use of a nucleic acid vaccine, which may also include a molecular adjuvant. Another significant patent addresses a novel method for producing catalytic antibodies, which exploits the products of catalysis to induce B cell mitogenesis. This method links a growth factor capable of inducing B cell mitogenesis to a target antigen, facilitating the generation of catalytic antibodies for therapeutic and diagnostic purposes.
Career Highlights
Throughout his career, Frank Koentgen has worked with various companies, including Amrad Operations Pty Ltd. His expertise in biotechnology has allowed him to contribute to advancements in the field, particularly in the area of antibody production.
Collaborations
Koentgen has collaborated with notable colleagues such as Gabriele Maria Suess and David Mathew Tarlinton. These partnerships have further enriched his research and development efforts in the field of catalytic antibodies.
Conclusion
Frank Koentgen's innovative work in the realm of catalytic antibodies showcases his dedication to advancing biotechnology. His patents reflect a commitment to developing methods that have the potential to impact therapeutic and diagnostic practices significantly.